Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants priority review to filing for Celgene's JAK2 inhibitor fedratinib in myelofibrosis

firstwordpharmaMarch 06, 2019

Tag: FDA , grants priority , Celgene

PharmaSources Customer Service